Trastuzumab
- Generic Name
- Trastuzumab
- Brand Names
- Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ontruzant, Perjeta-Herceptin, Phesgo, Trazimera, Herwenda, Ogivri, Zercepac, Tuznue
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 180288-69-1
- Unique Ingredient Identifier
- P188ANX8CK
- Background
Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic bre...
- Indication
For the adjuvant treatment of HER2-overexpressing breast cancer, trastuzumab is indicated in several clinical settings: as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; as part of a treatment regimen with docetaxel and carboplatin; or as monotherapy following multi-modality anthracycline-based th...
- Associated Conditions
- Breast Cancer, Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Adenocarcinoma of the Stomach, Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage I Breast Cancer
- Associated Therapies
- -
BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors
- First Posted Date
- 2022-09-26
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- BioInvent International AB
- Target Recruit Count
- 18
- Registration Number
- NCT05555251
- Locations
- 🇪🇸
Hospital Vall d'Hebron, Barcelona, Spain
🇪🇸Complejo hospitalario Ruber Juan Bravo, Madrid, Spain
🇬🇧Churchill Hospital, Oxford, United Kingdom
Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-08-25
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- Target Recruit Count
- 200
- Registration Number
- NCT05515796
- Locations
- 🇨🇳
Army Medical Center, Chongqing, Other (Non U.s.), China
Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-08-17
- Last Posted Date
- 2024-05-08
- Target Recruit Count
- 31
- Registration Number
- NCT05504720
- Locations
- 🇩🇪
Institut für Klinisch-Onkologische Forschung am Krankenhaus Nordwest, Frankfurt/main, Germany
🇩🇪Klinikum rechts der Isar der TU München, München, Germany
🇩🇪MVZ Onkologischer Schwerpunkt, Berlin, Germany
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Criterium, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05458674
- Locations
- 🇺🇸
Cancer Care Northwest, Spokane Valley, Washington, United States
🇺🇸University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
🇺🇸Swedish Cancer Institute, Issaquah, Washington, United States
Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2022-06-23
- Target Recruit Count
- 120
- Registration Number
- NCT05429684
- Locations
- 🇨🇳
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
🇨🇳Jin Yang, Xi'an, Shaanxi, China
A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2022-06-22
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Caigang Liu
- Target Recruit Count
- 136
- Registration Number
- NCT05426486
- Locations
- 🇨🇳
Shengjing Hospital affiliated to China Medical University, Shenyang, Liaoning, China
A Study for the Adjuvant Treatment of Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-06-15
- Last Posted Date
- 2022-07-01
- Target Recruit Count
- 2413
- Registration Number
- NCT05420467
- Locations
- 🇨🇳
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
A Study for the Neoadjuvant Treatment of Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-06-15
- Last Posted Date
- 2022-07-01
- Target Recruit Count
- 1576
- Registration Number
- NCT05420454
- Locations
- 🇨🇳
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 116
- Registration Number
- NCT05408845
- Locations
- 🇺🇸
UCSF Medical Center-Mission Bay, San Francisco, California, United States
🇺🇸Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States
Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C)
- Conditions
- Interventions
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2022-05-27
- Lead Sponsor
- Institut de cancérologie Strasbourg Europe
- Target Recruit Count
- 800
- Registration Number
- NCT05388500
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.